Search Results - "Groves, ES"

  • Showing 1 - 12 results of 12
Refine Results
  1. 1

    Intraventricular immunotoxin therapy for leptomeningeal neoplasia by Laske, D W, Muraszko, K M, Oldfield, E H, DeVroom, H L, Sung, C, Dedrick, R L, Simon, T R, Colandrea, J, Copeland, C, Katz, D, Greenfield, L, Groves, E S, Houston, L L, Youle, R J

    Published in Neurosurgery (01-11-1997)
    “…The goals of this clinical trial of intraventricular 454A12-rRA therapy were to identify dose-limiting toxicities, to evaluate the pharmacokinetics of…”
    Get full text
    Journal Article
  2. 2

    Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate by WEINER, L. M, O'DWYER, J, KITSON, J, COMIS, R. L, FRANKEL, A. E, BAUER, R. J, KONRAD, M. S, GROVES, E. S

    Published in Cancer research (Chicago, Ill.) (15-07-1989)
    “…Four women with metastatic breast cancer were treated with monoclonal antibody 260F9-recombinant ricin A chain, a ricin A chain immunoconjugate (IC) which…”
    Get full text
    Journal Article
  3. 3

    Phase I study of an anti-breast cancer immunotoxin by continuous infusion: report of a targeted toxic effect not predicted by animal studies by Gould, B J, Borowitz, M J, Groves, E S, Carter, P W, Anthony, D, Weiner, L M, Frankel, A E

    “…260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with approximately 50% of breast carcinomas, was given by continuous iv infusion…”
    Get more information
    Journal Article
  4. 4

    Role of the H-2 complex in the induction of T cell tolerance to self minor histocompatibility antigens by GROVES, E. S, SINGER, A

    Published in The Journal of experimental medicine (01-11-1983)
    “…The present study has utilized cytotoxic T lymphocyte (CTL) responses specific for minor histocompatibility (minor H) antigens as an experimental approach to…”
    Get full text
    Journal Article
  5. 5

    Intravenous administration of recombinant human macrophage colony-stimulating factor to patients with metastatic cancer: a phase I study by Sanda, M G, Yang, J C, Topalian, S L, Groves, E S, Childs, A, Belfort, Jr, R, de Smet, M D, Schwartzentruber, D J, White, D E, Lotze, M T

    Published in Journal of clinical oncology (01-10-1992)
    “…Recombinant human macrophage colony-stimulating factor (M-CSF) has been shown to stimulate specifically macrophage lineage differentiation in vitro and to…”
    Get more information
    Journal Article
  6. 6

    Phase I study of antilipopolysaccharide human monoclonal antibody MAB-T88 by DAIFUKU, R, HAENFTLING, K, YOUNG, J, GROVES, E. S, TURRELL, C, MEYERS, F. J

    Published in Antimicrobial Agents and Chemotherapy (01-10-1992)
    “…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
    Get full text
    Journal Article
  7. 7

    A phase I trial of recombinant human macrophage colony-stimulating factor by rapid intravenous infusion in patients with refractory malignancy by Zamkoff, K W, Hudson, J, Groves, E S, Childs, A, Konrad, M, Rudolph, A R

    Published in Journal of immunotherapy (01-02-1992)
    “…Twenty patients with advanced cancer for which there was no effective standard therapy or whose disease was refractory to standard therapy were treated with…”
    Get more information
    Journal Article
  8. 8

    Specific lysis of human tumor cells by T cells coated with anti-T3 cross-linked to anti-tumor antibody by Perez, P, Titus, JA, Lotze, MT, Cuttitta, F, Longo, DL, Groves, ES, Rabin, H, Durda, PJ, Segal, DM

    Published in The Journal of immunology (1950) (01-10-1986)
    “…Heteroaggregates containing anti-T3 cross-linked to anti-target cell antibodies have been shown to cause human T cells to lyse target cells that express…”
    Get full text
    Journal Article
  9. 9

    Adoptive immunotherapy of a syngeneic murine leukemia with a tumor- specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression by Matis, LA, Shu, S, Groves, ES, Zinn, S, Chou, T, Kruisbeek, AM, Rosenstein, M, Rosenberg, SA

    Published in The Journal of immunology (1950) (01-05-1986)
    “…The successful adoptive immunotherapy of the syngeneic Friend virus-induced murine leukemia FBL-3 was mediated by a proliferative MHC-restricted,…”
    Get full text
    Journal Article
  10. 10

    Suppression and transient induction of lymphokines in cancer patients after administration of polyethylene glycolated interleukin-2 by Shih, Y, Konrad, M W, Warren, M K, Childs, A, Paradise, C, Meyers, F J, Groves, E S

    Published in European journal of immunology (01-03-1992)
    “…Polyethylene glycolated (pegylated) interleukin-2 (PEG IL-2) was administered as a weekly i.v. bolus to patients with metastatic cancer in a phase-I trial…”
    Get more information
    Journal Article
  11. 11

    Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors by Pearson, J W, Fogler, W E, Volker, K, Riggs, C W, Gruys, E, Groves, E S, Wiltrout, R H, Longo, D L

    “…We have demonstrated that, in the human ovarian carcinoma cell line (OVCAR-3), recombinant human interferon alpha (rHuIFN-alpha) potentiated in vitro…”
    Get more information
    Journal Article
  12. 12

    Expression of MEL-14 antigen is not an absolute requirement for dissemination to lymph nodes after adoptive transfer of murine T lymphocyte clones by Bookman, MA, Groves, ES, Matis, LA

    Published in The Journal of immunology (1950) (01-10-1986)
    “…The inability of established antigen-specific murine T lymphocyte clones to recirculate well in vivo has been attributed to loss of the surface glycoprotein…”
    Get full text
    Journal Article